MedTrace Logo

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

NCT02715258 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2021-06-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).

Conditions

Interventions

DRUG

Bexagliflozin

tablets containing 20 mg bexagliflozin

DRUG

Placebo

tablets matching the appearance of bexagliflozin tablets

Sponsors & Collaborators

  • Theracos

    lead INDUSTRY

Principal Investigators

  • J. Paul Lock, MD · Theracos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02715258 on ClinicalTrials.gov